Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Reding MT"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 29
Tytuł:
Use of recombinant human antithrombin concentrate in pregnancy
Autorzy:
Baumann Kreuziger LM
Prosen TL
Reding MT
Pokaż więcej
Temat:
Gynecology and obstetrics
RG1-991
Źródło:
International Journal of Women's Health, Vol 2013, Iss default, Pp 583-586 (2013)
Opis pliku:
electronic resource
Relacje:
http://www.dovepress.com/use-of-recombinant-human-antithrombin-concentrate-in-pregnancy-a14366; https://doaj.org/toc/1179-1411
Dostęp URL:
https://doaj.org/article/14864e5ce53a4ffbab8539ea79a77677  Link otwiera się w nowym oknie
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey
Autorzy:
Reding MT
Cooper DL
Pokaż więcej
Temat:
Medicine (General)
R5-920
Źródło:
Journal of Multidisciplinary Healthcare, Vol 2012, Iss default, Pp 277-287 (2012)
Opis pliku:
electronic resource
Relacje:
http://www.dovepress.com/barriers-to-effective-diagnosis-and-management-of-a-bleeding-patient-w-a11371; https://doaj.org/toc/1178-2390
Dostęp URL:
https://doaj.org/article/bd7fe4e7f82f4eb5ac39f4611b93f122  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Tytuł:
A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report.
Autorzy:
Bishop AA; University of Minnesota Medical School Minneapolis Minnesota USA.
Krohn E; Department of Surgery University of Minnesota Minneapolis Minnesota USA.
Vakayil VR; Department of Surgery University of Minnesota Minneapolis Minnesota USA.
Pribyl K; Department of Surgery University of Minnesota Minneapolis Minnesota USA.
Reding MT; Department of Medicine University of Minnesota Minneapolis Minnesota USA.
Tignanelli C; Department of Surgery University of Minnesota Minneapolis Minnesota USA.
Harmon JV; Department of Surgery University of Minnesota Minneapolis Minnesota USA.
Pokaż więcej
Źródło:
Clinical case reports [Clin Case Rep] 2023 Jan 23; Vol. 11 (1), pp. e6831. Date of Electronic Publication: 2023 Jan 23 (Print Publication: 2023).
Typ publikacji:
Case Reports
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.
Autorzy:
Iorio A; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.; Hamilton-Niagara Hemophilia Program, Ontario, Canada.
Königs C; Clinical and Molecular Hemostasis, University Hospital Frankfurt, Goethe University, Department of Paediatrics, Frankfurt am Main, Germany.
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, Minnesota, USA.
Rotellini D; National Hemophilia Foundation, New York, New York, USA.
Skinner MW; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.; Institute for Policy Advancement, Ltd., Washington, District of Columbia, USA.
Mancuso ME; Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Berntorp E; Lund University, Skane University Hospital, Malmo, Sweden.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2023 Jan; Vol. 29 (1), pp. 33-44. Date of Electronic Publication: 2022 Oct 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hemophilia A*/complications
Hemophilia A*/drug therapy
Hemophilia A*/prevention & control
Hemophilia B*/complications
Hemophilia B*/drug therapy
Female ; Humans ; Quality of Life ; Blood Coagulation Factors/therapeutic use ; Hemorrhage/prevention & control ; Hemorrhage/drug therapy ; Factor VIII/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Autorzy:
Escobar M; Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA.
Luck J; Orthopaedic Hemophilia Treatment Center, Los Angeles, California, USA.
Averianov Y; City Research and Development Center for Diagnostics and Treatment of Patients with Abnormal Hemostasis, Kyiv, Ukraine.
Ducore J; Hematology/Oncology Clinic, University of California at Davis, Sacramento, California, USA.
Fernández MFL; Hemostasis and Thrombosis Unit, Teresa Herrera Hospital, A Coruña, Spain.
Giermasz A; Division of Hematology/Oncology, University of California at Davis, Sacramento, California, USA.
Hart DP; The Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry, QMUL, London, UK.
Journeycake J; Oklahoma Center for Bleeding and Clotting Disorders, Oklahoma City, Oklahoma, USA.
Kessler C; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, USA.
Leissinger C; Section of Hematology/Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Mahlangu J; Hemophilia Comprehensive Care Center, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
Martinez LV; Dr. José Eleuterio González Monterrey University Hospital, Monterrey, Nuevo León, México.
Miesbach W; Goethe University Hospital, Frankfurt, Germany.
Mitha IH; Lakeview Hospital, Benoni, Gauteng, South Africa.
Quon D; Orthopaedic Hemophilia Treatment Center, Los Angeles, California, USA.
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Schved JF; Haemophilia Treatment Centre, University Hospital Montpellier, Montpellier, France.
Stasyshyn O; Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine.
Vilchevska KV; National Specialized Children's Hospital Okhmatdyt, Kyiv, Ukraine.
Wang M; Hemophilia and Thrombosis Center, University of Colorado, Aurora, Colorado, USA.
Windyga J; Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Alexander WA; Aoede Associates, Athens, Texas, USA.
Al-Sabbagh A; LFB-USA, Inc., Framingham, Massachusetts, USA.
Bonzo D; LFB-USA, Inc., Framingham, Massachusetts, USA.
Mitchell IS; HEMA Biologics, LLC, Louisville, Kentucky, USA.
Wilkinson TA; GLOVAL LLC, Broomfield, Colorado, USA.
Hermans C; Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Nov; Vol. 27 (6), pp. 911-920. Date of Electronic Publication: 2021 Oct 06.
Typ publikacji:
Clinical Trial, Phase III; Journal Article
MeSH Terms:
Hemophilia A*/drug therapy
Hemostatics*/therapeutic use
Factor VIIa ; Hemostasis ; Humans ; Perioperative Care ; Recombinant Proteins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A.
Autorzy:
Santagostino E; Foundation IRCCS Ca' Granda, Maggiore Hospital Policlinico A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Lalezari S; Israel National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel.
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA.
Ducore J; Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA.
Ng HJ; Department of Haematology, Singapore General Hospital, Singapore.
Poulsen LH; The Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark.
Michaels LA; Bayer, Whippany, NJ, USA.
Linardi C; Bayer, Whippany, NJ, USA.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Jul; Vol. 27 (4), pp. e559-e562. Date of Electronic Publication: 2021 May 03.
Typ publikacji:
Letter
MeSH Terms:
Factor VIII*/therapeutic use
Hemophilia A*/drug therapy
Half-Life ; Humans ; Minor Surgical Procedures ; Polyethylene Glycols ; Treatment Outcome
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
Autorzy:
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA.
Pabinger I; University Clinic for Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Holme PA; Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Poulsen L; The Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark.
Negrier C; Hemophilia Comprehensive Care Center and Hematology Department, Louis Pradel University Hospital, Lyon, France.
Chalasani P; Division of Hematology and Oncology, University of Arizona Cancer Center, Phoenix, AZ, USA.
Maas Enriquez M; Bayer, Wuppertal, Germany.
Wang M; Bayer, Whippany, NJ, USA.
Meijer K; University Medical Center Groningen, Groningen, Netherlands.
Mancuso ME; Center for Thrombosis and Haemorrhagic Diseases, IRCCS Humanitas Clinical and Research Center, Rozzano, Italy.
Lalezari S; National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Aviv University, Tel Hashomer, Israel.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 May; Vol. 27 (3), pp. e347-e356. Date of Electronic Publication: 2021 Apr 05.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms:
Factor VIII*/therapeutic use
Hemophilia A*/drug therapy
Polyethylene Glycols*/therapeutic use
Humans ; Male ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027.
Autorzy:
Reding MT; University of Minnesota Medical Center, Minneapolis, MN, USA.
Pabinger I; Medical University of Vienna, Vienna, Austria.
Lalezari S; National Hemophilia Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel.
Santagostino E; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Mancuso ME; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2020 Jul; Vol. 26 (4), pp. e201-e204. Date of Electronic Publication: 2020 Jun 23.
Typ publikacji:
Letter
MeSH Terms:
Factor VIII/*therapeutic use
Hemophilia A/*drug therapy
Polyethylene Glycols/*therapeutic use
Factor VIII/pharmacology ; Female ; Humans ; Male ; Polyethylene Glycols/pharmacology
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Opioid exposure in haemophilia patients is common and underreported.
Autorzy:
Peltier SJ; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, United States.
Mazepa MA; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, United States.
Freese RL; Biostatistical Design and Analysis Center, University of Minnesota, Minneapolis, Minnesota, United States.
Nelson SF; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, United States.
Kearney SL; Center for Bleeding and Clotting Disorders, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States.
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, United States.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2020 Mar; Vol. 26 (2), pp. 251-256. Date of Electronic Publication: 2020 Feb 26.
Typ publikacji:
Journal Article
MeSH Terms:
Analgesics, Opioid/*therapeutic use
Hemophilia A/*drug therapy
Adolescent ; Adult ; Analgesics, Opioid/pharmacology ; Child ; Female ; Humans ; Male ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
Autorzy:
Lalezari S; Israel National Hemophilia Center, Chaim Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel.
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA.
Pabinger I; Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Holme PA; Department of Haematology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Negrier C; Hemophilia Comprehensive Care Center and Hematology Department, Louis Pradel University Hospital, Lyon, France.
Chalasani P; University of Arizona Cancer Center, Tucson, AZ, USA.
Shin HJ; Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea.
Wang M; Bayer, Whippany, NJ, USA.
Tseneklidou-Stoeter D; Bayer, Berlin, Germany.
Maas Enriquez M; Bayer, Wuppertal, Germany.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2019 Nov; Vol. 25 (6), pp. 1011-1019. Date of Electronic Publication: 2019 Oct 17.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms:
Safety*
Factor VIII/*adverse effects
Factor VIII/*pharmacology
Hemorrhage/*prevention & control
Polyethylene Glycols/*adverse effects
Polyethylene Glycols/*pharmacology
Adolescent ; Adult ; Child ; Dose-Response Relationship, Drug ; Female ; Hemophilia A/complications ; Hemorrhage/complications ; Humans ; Male ; Middle Aged ; Time Factors ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Overcoming the diagnostic and monitoring challenges for very rare bleeding disorders in the US: the potential benefits of a centralized laboratory.
Autorzy:
Chitlur M; Wayne State University, Children's Hospital of Michigan, Detroit, USA.
Pipe SW; University of Michigan, Ann Arbor, MI, USA.
Reding MT; University of Minnesota, Minneapolis, MN, USA.
Kessler CM; Georgetown University Medical Center, Washington, DC, USA.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2016 Jan; Vol. 22 (1), pp. 15-9.
Typ publikacji:
Editorial; Research Support, Non-U.S. Gov't
MeSH Terms:
Clinical Laboratory Techniques*
Blood Coagulation Disorders/*diagnosis
Blood Coagulation Disorders/drug therapy ; Humans ; Registries ; United States
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Is prophylaxis required for delivery in women with factor VII deficiency?
Autorzy:
Baumann Kreuziger LM; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN.
Morton CT
Reding MT
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2013 Nov; Vol. 19 (6), pp. 827-32. Date of Electronic Publication: 2013 Apr 22.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Review; Systematic Review
MeSH Terms:
Factor VII Deficiency/*drug therapy
Factor VIIa/*therapeutic use
Cesarean Section ; Databases, Factual ; Factor VII/analysis ; Female ; Hemorrhage/prevention & control ; Humans ; Odds Ratio ; Pregnancy ; Recombinant Proteins/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 29

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies